Anterior Uveitis Treatment Market Size, Share & Trends Report

Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, Immunosuppressants), By Distribution Channel (Hospital, Retail, Online Pharmacies), And Segment Forecasts, 2019 - 2026

  • Published Date: Aug, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-3-68038-450-5
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 120

Industry Insights

The global anterior uveitis treatment market size was valued at USD 276.78 million in 2018 and is expected to witness a CAGR of 5.4% over the forecast period. Rising incidence of anterior uveitis is majorly driving growth. This disease causes inflammation in anterior part of the uvea of eye. Treatment for such sight threatening diseases primarily includes corticosteroids and immunosuppressive agents. In most of the cases, corticosteroid eye drops are prescribed.

Anterior uveitis could arise due to various other diseases as well, which increases its prevalence. National Health Service, U.K., states that corticosteroid prescription depends on the type of uveitis, as it works by disturbing the normal operations of the immune system. In 2017, 12.7% of the world’s population was over 60 years, and it is expected to increase in the coming years. The predisposition to this disease increases with age.

North America anterior uveitis treatment market

New developments in applications of products and treatment modalities are ongoing, for instance, Humira’s approval for treatment of uveitis was a major breakthrough. Hence, factors such as growing geriatric population, rising incidence of the disease, and new product developments are expected to be some of the driving factors. Redness of eyes, blurring of vision, small size of pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness.

Increasing incidence of optical infections coupled with rising awareness about various treatments is likely to aid market growth over the forecast period. High expenditure on healthcare, increasing disposable income, and favorable government regulations are some other drivers of the market. Anterior uveitis is one of the common ocular inflammation types that is reported to primary eye care professionals.

Patients with anterior uveitis might have altered Intraocular Pressure (IOP). As a result, blood might cover the anterior chamber, affecting visual acuity. Corticosteroid treatment can result in IOP elevation, which is an adverse effect of the drug type. Some of the major complications associated with this type of eye disease are glaucoma, cataract, cystoid macular edema, and band keratopathy.

Treatment Type Insights

There are various types of treatments available: corticosteroids, immunosuppressants, cycloplegic agents, and anti-TNF agents. Corticosteroids dominated the anterior uveitis treatment market in 2018, as they are first line therapies for anterior uveitis. They are used in the form of eye drops as well as systematic therapy. Corticosteroids are also used in sustained release treatment, i.e., in ocular implants. Some of the topical corticosteroid drugs commonly available are prednisolone acetate, betamethasone, dexamethasone sodium phosphate, fluorometholone, loteprednol, and rimexolone.

The anti-TNF agents are used as anti-inflammatory agents, while cycloplegic agents are useful in both diagnosis and treatment of the disease. On the other hand, immunosuppressant drugs act by distorting normal functioning of immune system to relive inflammation. These drugs are mainly used in corticosteroid-resistant cases or chronic uveitis cases.

Distribution Channel Insights

On the basis of distribution channel, hospital pharmacies held the largest share in 2018 due to availability of a wide array of options for management of eye inflammation. Moreover, hospitals provide treatment & care to a large number of patients, making hospital pharmacies a leading segment.

Canada anterior uveitis treatment market

Online pharmacies are expected to show lucrative growth during the forecast period, due to the convenience of delivering the medicines at doorstep. The discounted price that the online pharmacies provide is also a factor that drives the market growth. Although hospital pharmacies have shown a trend of price hike in recent years, their location gives an advantage.

Regional Insights

North America dominated the market in 2018 owing to the rising prevalence of the disease in the U.S. Presence of key players in the region is also leading to high growth of this regional segment. Development of new methods, such as stem cell therapy, for treatment of ocular diseases and approval of drugs like Humira for treatment of this condition are some of the major driving factors.

Increase in per capita healthcare expenditure and rising prevalence of the disease are some of the factors driving the market in the European region. Asia Pacific region is expected to show lucrative growth over the forecast period, owing to presence of a large population. In addition, rising prevalence of this condition is also a factor that can be attributed to regional growth. According to NCBI, sarcoidosis, Vogt-Koyanagi-Harada disease, and Behcet’s disease are very common in the Asia Pacific countries and these conditions can result in anterior uveitis.

Anterior Uveitis Treatment Market Share Insights

Some major players of anterior uveitis treatment market are Novartis AG; Santen Pharmaceutical Co., Ltd; AbbVie Inc.; Eyegate Pharmaceuticals, Inc.; Clearside Biomedical, Inc.; Aldeyra Therapeutics, Inc.; Aciont Inc.; Sirion Therapeutics, Inc.; UCB Biopharma S.P.R.L.; and Lux Biosciences, Inc. Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2018, Clearside Biomedical, Inc. submitted a New Drug Application (NDA) to the U.S. FDA for its XIPERE that is intended for treating uveitic macular edema.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historic data

2015 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million & CAGR from 2019 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2015 - 2026. For the purpose of this study, Grand View Research has segmented the anterior uveitis treatment market report on the basis of treatment type, distribution channel, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)

    • Corticosteroids

    • Cycloplegic Agents

    • Anti-TNF Agents

    • Immunosuppressants

  • Distribution Channel Outlook (Revenue, USD Million, 2015 - 2026)

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • Regional Outlook (Revenue, USD Million, 2015 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • MEA

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified